News Related to Viatris

Related coverage linked through entity extraction aliases.

EMA Approves Shield Therapeutics' FeRACCRU for Adolescents Following FDA Pediatric Authorization

Mar 31, 2026

The European Medicines Agency has approved Shield Therapeutics' FeRACCRU® for adolescents aged 12 and older, following FDA approval of ACCRUFeR® for children 10+. The expansion was supported by Phase 3 pediatric trial data showing efficacy and safety in children as young as 1 month.

FDA Accepts Viatris Presbyopia Treatment Application, Approves Rival Eye Drop Therapy

Feb 25, 2026

The FDA accepted Viatris' application for phentolamine ophthalmic solution 0.75% to treat presbyopia, with a decision expected October 2026. Separately, the agency approved Yuvezzi, a once-daily combination eye drop for age-related near vision loss.